Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Rating of “Hold” from Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given a consensus recommendation of “Hold” by the five ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.3333.

Several research firms recently weighed in on ATOS. Zacks Research lowered Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Ascendiant Capital Markets raised their price target on shares of Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday.

Atossa Genetics Price Performance

ATOS opened at $0.65 on Friday. The business has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $0.81. Atossa Genetics has a 1 year low of $0.55 and a 1 year high of $1.29. The company has a market capitalization of $84.55 million, a PE ratio of -2.73 and a beta of 1.09.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). Equities analysts anticipate that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atossa Genetics

Several hedge funds have recently modified their holdings of ATOS. Y Intercept Hong Kong Ltd acquired a new position in shares of Atossa Genetics in the second quarter valued at approximately $321,000. Bank of America Corp DE boosted its position in Atossa Genetics by 55.8% during the 3rd quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock worth $135,000 after buying an additional 55,568 shares during the period. Squarepoint Ops LLC grew its holdings in Atossa Genetics by 39.9% during the 3rd quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock worth $220,000 after acquiring an additional 72,235 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Atossa Genetics by 509.0% during the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock worth $269,000 after acquiring an additional 259,725 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after acquiring an additional 245,717 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.